(Press-News.org) Boston – Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial. The trial, led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Cancer at Dana-Farber Cancer Institute, showed the risk of progression was reduced by 25-26%.
The results were presented at the annual European Society for Medical Oncology (ESMO) Congress on October 21, 2023, in Madrid, Spain.
“This is real progress for patients and could lead to approval of this drug for this patient group,” says Choueiri, senior author on the presentation in Madrid.
Belzutifan, a HIF-2α inhibitor, is currently approved for patients with Von Hippel-Landau (VHL) disease-associated renal cell carcinoma, a form of kidney cancer. The drug was originally investigated and approved for kidney cancer patients with VHL disease because they have inherited a mutation that inactivates the VHL gene, which results in an overabundance of HIF-2α in cells.
When overabundant in cells, HIF-2α is associated with increased cancer-driving activity, such as cell proliferation, immune evasion, low oxygen levels (called hypoxia), and blood vessel formation (called angiogenesis). Dana-Farber’s William G. Kaelin, Jr., MD, was awarded a Nobel Prize in Physiology or Medicine in 2019 for the discovery of the role HIF-2α in cancer and other diseases.
“The knowledge we have about hypoxia and angiogenesis in kidney cancer stemmed from this essential pre-clinical research at Dana-Farber,” says Choueiri. “Bringing this knowledge forward to benefit patients is very gratifying.”
While the mutation that causes VHL disease is inherited, spontaneous mutations that inactivate VHL occur in over 90% of ccRCC tumors, suggesting that a HIF-2α inhibitor might also benefit patients with ccRCC.
This trial, called LITESPARK-005, enrolled 746 patients with metastatic ccRCC who had progressed after treatment with both an immune checkpoint inhibitor (ICI), such as a PD-1 or PD-L1 inhibitor, and an anti-angiogenic therapy. ICIs and anti-angiogenic medicines have become a standard part of first- and second-line therapies for metastatic ccRCC, though most patients eventually experience disease progression and need additional treatment options.
Patients were randomized to receive treatment with either belzutifan or everolimus. At the second interim analysis, after a median of 25.7 months, patients taking belzutifan were 26% less likely to have progressed compared with those taking everolimus.
The overall response rate was also higher with belzutifan, at 22% versus 3.5%, and 13 patients experienced a complete response with belzutifan compared to none with everolimus. Patients taking belzutifan were also less likely to discontinue therapy due to side effects.
“Importantly, quality of life favored belzutifan,” says Choueiri.
There was an improvement in overall survival with belzutifan though it was not statistically significant.
This investigation of monotherapy with belzutifan is part of a broader strategy to learn more about the efficacy and safety of HIF-2α inhibition in RCC. The strategy involves multiple LITESPARK trials examining beluzutifan alone and in combination with other therapies in treatment-naive and pre-treated disease settings. Choueiri also presented updated findings from the phase 2 LITESPARK-003 at the ESMO Congress that showed belzutifan plus cabozantinib showed durable antitumor activity and a safety profile consistent with prior observation previously published in The Lancet Oncology.
Both trials are sponsored by Merck Sharp & Dohme LLC.
ESMO Session Details
LBA 87: Phase 2 LITESPARK-003 Study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC) will be presented in Proffered Paper Session 2 – Genitourinary tumors, non-prostate on Saturday, October 21, 2023, at 8:45am ET (14:45 CEST) Toni K. Choueiri, MD/First Author
LBA 88: Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase 3 LITESPARK-005 study will be presented in Proffered Paper Session 2- Genitourinary tumors, non-prostate on Saturday, October 21, 2023, at 8:55am ET (14:55 CEST) Toni K. Choueiri, MD/Senior Author
For all ESMO-related media inquiries, call or email Victoria Warren, 617-939-5531, Victoria_Warren@dfci.harvard.edu. Follow the meeting live on X (Twitter) using the hashtag #ESMO23 and follow Dana-Farber News on X (Twitter) at @DanaFarberNews.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.
We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
###
END
The following Lancet papers will be presented at the European Society for Medical Oncology Congress 2023 (#ESMO 2023). The conference will take place between Friday 20th – Tuesday 24th October 2023.
Contact details for corresponding authors are provided should you wish to arrange an interview with the authors. Funding information is listed on the first page of each Article.
**Embargo: 13.00 [BST] / 14.00 [CEST] Friday 20th October 2023**
The Lancet: Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase ...
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.
The results will be presented at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Oct. 23, 2023 (poster 1887P) by Primo N. Lara, Jr., MD, lead author on the abstract. ...
Media contacts: Lisa Black, lblack@aap.org; or Adam Alexander, aalexander@aap.org
The parent’s universal cry in response to loud music-- “Turn that thing down!” -- is well-founded, as evidence shows that children and teens risk hearing loss by cranking up their personal listening devices. What families may not realize is that children are exposed to potentially harmful noise from infancy and that the effects are cumulative over a lifetime.
The American Academy of Pediatrics discusses the common sources and effects of noise, from infant sleep ...
Four senior bioengineering students at The University of Texas at Arlington have won the Biomedical Engineering Society (BMES) Coulter College for Healthcare Innovation competition for their work on an early detection device for atrial fibrillation.
Brady Killham, Juan Ramirez, Jeannette Santos and Michael Ikefuna, all seniors in UTA’s Bioengineering Department, earned the Best Overall award for their plan to develop FibGuard, a wearable, non-invasive atrial fibrillation early detection device.
UTA competed against teams from Vanderbilt, Purdue, Virginia Tech, Wake Forest, Texas A&M, the University of Oklahoma and Rensselaer Polytechnic ...
BIRMINGHAM, Ala. – Lung development in the fetus occurs at low oxygen tension in the womb, but after a very premature birth, the partly developed lungs of the tiny infants experience far greater oxygen tensions even without the prolonged supplemental oxygen that is often required. This can produce well-known disastrous effects on the structure and function of the neonatal lung, causing the serious lung condition of bronchopulmonary dysplasia in high-risk premature infants.
Using a neonatal mouse model, researchers ...
“The majority of wound infections often manifest themselves immediately postoperatively, so close followup should take place [...]”
BUFFALO, NY- October 20, 2023 – A new research perspective was published in Oncoscience (Volume 10) on October 4, 2023, entitled, “Diagnosis and management of postoperative wound infections in the head and neck region.”
In everyday clinical practice at a department for oral and maxillofacial surgery, a large number of surgical procedures in the head and neck region take place under both outpatient and inpatient conditions. The basis ...
The Brain & Behavior Research Foundation announced it is awarding $10.2 million in Young Investigator Grants to 150 promising early career scientists who are working to identify causes, improve treatments, and develop methods of prevention for psychiatric illnesses that impact millions of people in the United States and around the world.
The 2023 Young Investigators are focused on a broad range of psychiatric illnesses. More than half of the projects are relevant to the study or treatment of depression and schizophrenia. Addiction/substance-use disorders, anxiety, and ...
Cannabis use, even for medical purposes, could make some people sick due to harmful fungi that contaminate the plants.
That is the finding of a recently published peer-reviewed journal article, whose authors recommend further study and consideration of changes to regulations to protect consumers, especially those who are immunocompromised. They examined data, previous studies, and U.S. and international regulations related to the cannabis and hemp industry.
The article was published in Frontiers in Microbiology. It was researched and written by Kimberly Gwinn, professor of entomology and plant pathology at the University of Tennessee Institute ...
Since 2011, California has significantly reformed its criminal justice system, reducing the size of its prison population, with no effect on violent crime and only marginal impacts on property crime statewide. The COVID-19 pandemic furthered decarceration as the state reduced state prison and jail populations to slow the spread of the virus. Concerns emerged that releases under the auspices of COVID mitigation harmed public safety. A new study explored this notion and found no consistent relation between COVID-19-related jail decarceration and violent or property ...
It’s a familiar story to many of us: In prehistoric times, men were hunters and women were gatherers. Women were not physically capable of hunting because their anatomy was different from men. And because men were hunters, they drove human evolution.
But that story’s not true, according to research by University of Delaware anthropology professor Sarah Lacy, which was recently published in Scientific American and in two papers in the journal American Anthropologist.
Lacy and her colleague Cara Ocobock from the University of Notre Dame examined the division of labor according to sex during the Paleolithic era, approximately 2.5 million to 12,000 ...
